Comment on Durrani et al.’s “Adalimumab for Ocular Inflammation”

M. E. A. GhembazaDepartment of Internal Medicine, Hospital University Tidjani Damerdji, Tlemcen, Algeria;Faculty of Medical Sciences Tlemcen, Hospital University Tidjani Damerdji, Tlemcen, AlgeriaCorrespondence[email protected]

, MD &

Ali LouniciDepartment of Internal Medicine, Hospital University Tidjani Damerdji, Tlemcen, Algeria;Faculty of Medical Sciences Tlemcen, Hospital University Tidjani Damerdji, Tlemcen, Algeria

, PhD

References

Durrani K, Kempen JH, Ying GS, et al. Adalimumab for ocular inflammation. Ocul Immunol Inflamm. 2016;22:1–8.
PubMed Web of Science ®Google Scholar
Vallet H, Seve P, Biard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis. Arthritis Rheum. 2016;68:1522–1530.
PubMed Web of Science ®Google Scholar
Eb R, Me F, Maia M, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009;28:117–144.
PubMed Web of Science ®Google Scholar
Levy-Clarke G, D A J, R W R, et al. expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785–796e3.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Comment on Durrani et al.’s “Adalimumab for Ocular Inflammation”

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Comment on Durrani et al.’s “Adalimumab for Ocular Inflammation”

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date